Sign in
Taking people in South KoreaPhase 3

Raludotatug deruxtecan with or without bevacizumab as maintenance for newly diagnosed advanced ovarian cancer

Tests raludotatug deruxtecan, with or without bevacizumab, in adults after ovarian cancer chemotherapy.

Key facts

Who runs it
Merck Sharp & Dohme LLC
Where
Seoul, South KoreaSee the 2 sitesAlso in 4 other countries, 11 sites
Trial code
Registry title
A Study of Raludotatug Deruxtecan With or Without Bevacizumab as First-Line Maintenance Treatment in Non-HRD-Positive Advanced Ovarian Cancer (MK-5909-006, (ENGOT-ov102/GOG-3141/ REJOICE-Ovarian 04)
Status
Recruiting
Phase
Phase 3
People taking part
802 people, planned
Started
18 Sept 2026
Expected to end
22 Oct 2034
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • R-DXd
  • Bevacizumab
Record updated
5 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for women with newly diagnosed advanced ovarian, fallopian tube or primary peritoneal cancer who finished first-line platinum chemotherapy and whose tumour is not HRD-positive.

Age
18 years or older
Sex
Women only
Disease stage
New diagnosis of FIGO Stage III or Stage IV high grade serous or high grade endometrioid ovarian cancer, fallopian tube cancer or primary peritoneal cancer. The tumour must not be HRD-positive.
Earlier treatment
Must have had debulking surgery (primary or interval) and finished first-line platinum-based chemotherapy with stable disease, partial response, complete response or no evidence of disease. No other earlier anticancer drug treatment.
Biomarker or test result
Tumour tissue that was not irradiated before. The central laboratory must show the tumour is not HRD-positive. Unknown or inconclusive HRD status is not allowed.

Main reasons for not taking part

  • Other tumour types, such as mucinous, borderline, malignant Brenner's or undifferentiated tumours
  • Current or past inflammatory bowel disease needing immune-suppressing medicine
  • Current bowel obstruction, abdominal fistula or gut perforation
  • Severe lung problems
  • Another cancer that is growing or needed treatment in the past 3 years

The registry criteria, word for word

Show all 19 criteriaShow less

Who can take part

  • The main inclusion criteria include but are not limited to the following:
  • Has a new, histologically confirmed diagnosis of International Federation of Gynecology and Obstetrics (FIGO) Stage III or Stage IV epithelial ovarian cancer (EOC) (high grade serous or high grade endometrioid), fallopian tube cancer, or primary peritoneal cancer
  • Has undergone primary debulking surgery (PDS) or interval debulking surgery (IDS)
  • Has completed first-line (1L) platinum-based chemotherapy, with a response of stable disease, partial response, complete response or no evidence of disease per protocol
  • Has provided tumor tissue that is not previously irradiated
  • Who have AEs due to previous anticancer therapies must have recovered to Grade ≤1 or baseline (except alopecia or vitiligo), as assessed by the physician investigator
  • Human immunodeficiency virus (HIV)-infected participants must have well-controlled HIV on antiretroviral therapy (ART)

Who cannot take part

  • Has received 1L platinum-based chemotherapy without bevacizumab and have a response of SD or PR at the time of screening
  • Has received prior systemic anticancer therapy, with the exception of the first-line platinum-based chemotherapy required by the inclusion criteria
  • Has not recovered from major surgery or has ongoing surgical complications
  • Has active inflammatory bowel disease requiring immunosuppressive medication or previous history of inflammatory bowel disease
  • Has clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses including, but not limited to, any underlying pulmonary disorder or prior pneumonectomy
  • Has non-serous or non-endometrioid high-grade epithelial histology, nonepithelial ovarian cancers, borderline tumors, mucinous tumor, seromucinous tumor that is predominately mucinous, malignant Brenner's tumor, and undifferentiated carcinoma
  • Has current, clinically relevant bowel obstruction including obstruction related to underlying EOC, abdominal fistula or gastrointestinal perforation, intra-abdominal abscess, or evidence of rectosigmoid involvement by pelvic exam
  • HIV-infected participants with a history of Kaposi's sarcoma and/or multicentric Castleman disease
  • Has known additional malignancy that is progressing or has required active treatment within the past 3 years
  • Has active infection requiring systemic therapy
  • Has a homologous recombination deficiency (HRD)-positive, unknown, or inconclusive tumor status as determined by the central laboratory
  • The main exclusion criteria include but are not limited to the following:

Where in South Korea

Also in 4 other countries, 11 sites

  • Samsung Medical Center (Site 2303)Seoul, South KoreaContact: Study CoordinatorTaking people
  • Seoul National University Hospital (Site 2301)Seoul, South KoreaContact: Study CoordinatorTaking people

About the trial

What the trial wants to find out

Researchers are looking for new ways to treat ovarian cancer (OC). Current treatment for OC may start with surgery to remove as much of the cancer as possible. After surgery, people may receive chemotherapy. After chemotherapy, standard care options may include:

Read full original descriptionShow less

Maintenance treatment, which is used after another therapy to keep the cancer from growing, spreading, or coming back. Bevacizumab is a targeted therapy used as standard maintenance treatment. Targeted therapy works to control how specific types of cancer cells grow and spread.

Observation, which is watching to see if cancer grows or worsens. The study medicine, raludotatug deruxtecan- R-DXd, is a targeted therapy. The goal of this study is to learn if people who receive R-DXd maintenance treatment with or without bevacizumab live longer without the cancer getting worse than people who receive standard care.

The 2 groups in the trial

  • Arm 1: R-DXd with or without bevacizumabTreatment being tested

    Participants will receive intravenous (IV) raludotatug deruxtecan (R-DXd)with or without IV bevacizumab for up to 2 years until progressive disease (PD), unacceptable toxicity, or other protocol-specified reason for discontinuation.

    Treatment: R-DXd and Bevacizumab

  • Arm 2: Standard of care (bevacizumab or observation only)Existing treatment, for comparison

    Participants will receive bevacizumab 15 mg/kg IV q3w for up to 22 cycles (each cycle=21 days) until disease progression, prohibitive toxicity, or other protocol-defined reason for discontinuation of study intervention or will be observed and actively followed if not receiving bevacizumab.

    Treatment: Bevacizumab

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
A Phase 3, Randomized, Open-label Study of Raludotatug Deruxtecan (MK-5909, R-DXd) Maintenance Treatment With or Without Bevacizumab Versus Standard of Care in Participants With Newly-Diagnosed Advanced Non-HRD-Positive Ovarian Cancer Following First-line Platinum-based Chemotherapy (ENGOT-ov102/MITO/GOG-3141/ REJOICE-Ovarian 04)
Plain-language title
Raludotatug deruxtecan with or without bevacizumab as maintenance for newly diagnosed advanced ovarian cancerGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
5 November 2026